MedTrace Logo

Mechanical Opening Device Implantation Following Intravenous r-tPA for Recanalization in Acute Ischemic Stroke

NCT02347358 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2015-01-27

No results posted yet for this study

Summary

This study is to test a hypothesis that temporary implantation of JRecanTM blood flow recanalisation device within 6.5 hours of symptom onset of acute ischemic stroke due to a major intracranial artery occlusion following IV r-tPA can provide a greater rate of early successful recanalisation than treatment of IV r-tPA alone.

Conditions

  • Ischemic Cerebrovascular Accident

Interventions

DEVICE

JRecanTM blood FR device

JRecanTM blood flow recanalisation device

DRUG

IV r-tPA

intravenous recombinant human tissue plasminogen activator

Sponsors & Collaborators

  • Hunan Rui Kang Tong technology development co., LTD

    collaborator UNKNOWN

  • The Second Artillery General Hospital

    lead OTHER

Principal Investigators

  • Weijian Jiang, MD,PhD · New Era Stroke Care and Research Institute, The Second Artillery General Hospital Beijing

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2017-01-31
Completion
2017-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02347358 on ClinicalTrials.gov